Abstract
This controlled, double-blind, study assessed the renal impact of early (< 12 hr postnatal age) indomethacin [I], for prevention of patent ductus arteriosus (PDA), in O2 dependent inborn infants with birth weights (BW)≤1300 gm. Fifty infants randomly received 3 IV doses of [I] or placebo [P] at 12 hr intervals. Dose1 (D1) was 0.2 mg/kg;D2 and D3 were 0.1 mg/kg each. Fluid balance, serum sodium (Na), potassium (K), creatinine (Cr), blood urea nitrogen (BUN) and fractional Na excretion (FENa) were evaluated pre-D1, 6-12 hr post-D1, 12-36 hr post-D3, and 1 wk post-D3. Timed urine specimens were used to derive Cr clearance (CCr) post-D3 and 1 wk post-D3. The 25 infants in each group were comparable in BW, gestational age, APGARs, pH and base excess at study entry. [I]-treated infants had reduced urine output (UO) in the 12 hr period following D1 that was no longer evident post-D3. Fluid intake, Na, K, BUN, Cr, FENa, and CCF were similar throughout the study. Renal data (x±SEM) revealed:
In contrast to reports of renal dysfunction induced by indomethacin therapy for symptomatic PDA, early [I] appears to alter renal function minimally in prematures without significant PDA.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nystrom, G., Setzer, E., Zilleruelo, G. et al. 406 PROPHYLACTIC INDOMETHACIN: EFFECTS ON RENAL FUNCTION. Pediatr Res 19, 178 (1985). https://doi.org/10.1203/00006450-198504000-00436
Issue Date:
DOI: https://doi.org/10.1203/00006450-198504000-00436